Objective: We aimed to clarify the relationship between aphasia and hematoma type/volume in patients with left putaminal hemorrhage admitted to a rehabilitation facility. Methods: We evaluated the relationship between the presence, type, and severity of aphasia and hematoma type/volume in 92 patients with putaminal hemorrhage aged 29-83 years. Hematoma type and volume were evaluated on the basis of CT images obtained at stroke onset. The Standard Language Test for Aphasia was conducted as part of the initial assessment. Results: Aphasia was observed in 79 of 92 patients. A total of 31 patients had fluent aphasia, while 48 had non-fluent aphasia. Non-fluent aphasia often involved hematoma on the anterior limb of the internal capsule, while fluent aphasia often involved hematoma on the posterior limb of internal capsule. When the hematoma volume exceeded 20 mL, patients experienced difficulty in repeating spoken words. When hematoma volume exceeded 40 mL, non-fluent aphasia was observed in all patients. Conclusion: Our findings suggest that hematoma type and volume not only influence the development of aphasia following putaminal hemorrhage but also play a major role in determining the patient's fluency and repetition ability.

1.
Takizawa T: Frequency of causes, location, age, and gender in cerebral hemorrhage; in Kobayashi S (ed): Stroke Databank 2015. Tokyo, Nakayama Shoten, 2015, pp 132-133.
2.
Sugimoto K, Minematsu K, Yamaguchi T: [Aphasia and size of hematoma in patients with left putaminal hemorrhage]. Rinsho Shinkeigaku 1989;29:574-578.
3.
Horikoshi T, Magaseki Y, Omata T, Hashizume K, Nukui H, Komiya K: [Speech disturbance in acute stage of putaminal hemorrhage]. No Shinkei Geka 1993;21:411-416.
4.
Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, et al: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870.
5.
Raven JC: Coloured Progressive Matrices. London, Oxford Psychologists Press, 1976.
6.
Hasegawa T, Kishi H, Shigeno K, et al: Three-dimensional structure in language tests of aphasia. Folia Phoniat (Basel) 1985;37:246-258.
7.
Kanaya H, Saiki I, Ohuchi T, Kamata K, Endo H, Mizukami M, Kagawa, M, Kaneko, M, Ito Z: Update on surgical treatment; in Mizukami M, Kogure K, Kanaya H (eds): Hypertensive Intracerebral Hemorrhage. New York, Raven Press, 1983, pp 147-163.
8.
Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J: The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996;27:1304-1305.
9.
Benson DF: Aphasia, Alexia, and Agraphia. London, Churchill Livingstone, 1979.
10.
Fukatsu R, Fujii T, Narikawa H, Kimura I, Saso S, Yoshioka Y, Hagimoto Y: Left putaminal hemorrhage and aphasia. Iryo 1993;47:599-602.
11.
Hier DB, Davis KR, Richardson EP Jr, Mohr JP: Hypertensive putaminal hemorrhage. Ann Neurol 1977;1:152-159.
12.
Alexander MP, LoVerme SR Jr: Aphasia after left hemispheric intracerebral hemorrhage. Neurology 1980;30:1193-1202.
13.
Naeser MA, Alexander MP, Helm-Estabrooks N, Levine HL, Laughlin SA, Geschwind N: Aphasia with predominantly subcortical lesion sites: description of three capsular/putaminal aphasia syndromes. Arch Neurol 1982;39:2-14.
14.
Otsuki M: Localization of language. Higher Brain Funct Res 2007;27:231-243.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.